Table 4 Univariate analyses of factors associated with survival and recurrence

Age (year)

0.982 (0.958-1.006)

0.142

0.976 (0.953-0.999)

0.043

Sex (female vs. male)

0.630 (0.250-1.588)

0.298

0.673 (0.288-1.574)

0.361

Hepatitis history (no vs. yes)

1.384 (0.498-3.848)

0.534

0.874 (0.395-1.935)

0.739

Liver cirrhosis (no vs. yes)

1.855 (0.746-4.657)

0.190

0.904 (0.455-1.797)

0.773

AFP(ng/ml) (≤ 20 vs. >20)

2.183 (1.175-4.035)

0.013

2.553 (1.401-4.651)

0.002

ALT(U/L) (≤ 40 vs. >40)

0.877 (0.502-1.533)

0.645

0.817 (0.476-1.401)

0.463

γ-GT(U/L) (≤ 54 vs. >54)

2.475 (1.313-4.664)

0.005

1.555 (0.888-2.722)

0.123

Tumor differentiation (I+II vs. III+IV)

1.860 (1.062-3.297)

0.030

1.180 (0.691-2.014)

0.545

Tumor size (cm)

1.179 (1.109-1.253)

0.001

1.152 (1.083-1.226)

0.001

Tumor number (single vs. multiple)

1.597 (0.860-2.966)

0.138

2.851 (1.611-5.046)

0.001

Vascular invasion (no vs. yes)

5.706 (2.971-10.960)

0.001

4.028 (2.288-7.089)

0.001

Encapsulation (complete vs. no)

2.060 (1.135-3.737)

0.017

3.273 (1.773-6.044)

0.001

BCLC stage (A vs. B+C)

6.225 (2.645-14.647)

0.001

2.601 (1.390-4.867)

0.003

COX-2 mRNA (low vs. high)

2.042 (1.157-3.604)

0.014

1.839 (1.068-3.167)

0.027

MMP7 mRNA (low vs. high)

2.278 (1.297-4.001)

0.004

0.753 (0.409-1.384)

0.060

MMP9 mRNA (low vs. high)

0.740 (0.412-1.328)

0.313

1.711 (0.977-2.995)

0.609

VEGF mRNA (low vs. high)

1.370 (0.756-2.483)

0.299

1.906 (1.096-3.126)

0.022

PDGFRA mRNA (low vs. high)

1.801 (1.017-3.188)

0.044

1.771 (1.023-3.066)

0.041

MYC mRNA (low vs. high)

0.948 (0.517-1.735)

0.862

0.867 (0.501-1.499)

0.361

HIF-1α mRNA (low vs. high)

2.644 (1.524-4.655)

0.001

2.514 (1.462-4.324)

0.001

HIF-1α protein (low vs. high)

1.874 (1.074-3.270)

0.027

2.004 (1.167-3.440)

0.012